Skip to main content

Table 1 Clinical features of the patient group.

From: The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency

 

Whole group n = 424

Decline group n = 110

Emphysema

Bronchiectasis

Chronic bronchitis

   

Yes n = 279

No n = 70

Yes n = 83

No n = 266

Yes n = 159

No n = 265

Gender (% male)

59.91

66.36

64.16

54.29

57.83

63.67

64.78

57.03

Age (years)

50.01 (0.52)

51.48 (0.92)

51.76 (0.78)

41.52 (33.77–49.27)

54.18 (1.03)

48.90 (0.63)

50.79 (0.77)

49.48 (0.69)

Pack years

14.00 (2.35–25.65)

18.75 (9.01–28.49)

17.50 (7.65–27.35)

0 (0–4.18)

14.63 (4.33–25.93)

13.50 (1.40–24.60)

14.63 (2.55–26.71)

12.75 (0.75–24.75)

FEV1 %predicted

37.15 (18.30–56.04)

35.01 (18.25–51.77)

32.08 (18.94–45.22)

102.88 (80.93–124.83)

36.64 (14.59–58.69)

35.54 (17.39–53.69)

32.76 (15.49–50.03)

38.17 (14.18–62.16)

FEV1/FVC

38.40 (25.95–50.85)

37.30 (27.10–48.40)

35.00 (26.00–44.00)

73.60 (63.10–84.10)

40.10 (24.35–55.85)

37.50 (25.00–48.00)

37.85 (26.85–48.85)

39.40 (26.40–52.40)

KCO %predicted

69.82 (1.18)

68.09 (2.12)

63.18 (1.38)

98.66 (2.55)

67.85 (2.75)

70.57 (1.54)

67.62 (2.31)

71.34 (1.89)

UZVI

31.09 (1.05)

32.84 (1.69)

32.71 (1.02)

2.31 (0.39)

33.45 (1.89)

30.63 (1.27)

32.98 (1.69)

29.88 (1.36)

LZVI

44.59 (1.21)

52.10 (38.53–65.68)

46.78 (1.14)

5.85 (1.01)

54.15 (39.50–68.80)

47.95 (32.15–63.75)

48.85 (34.60–63.10)

49.50 (31.90–67.10)

Decline of FEV1 (ml/yr)

 

31.3 (4.1)

      
  1. Data is presented as mean (SEM) or median (IQR) dependent on its distribution. UZVI = upper zone voxel index, LZVI = lower zone voxel index. The only significant difference between the decline group and the whole dataset was that they had smoked more (p = 0.01).